1,3, 4-oxadiazole neuraminidase inhibitor and preparation method and application thereof

文档序号：61636 发布日期：2021-10-01 浏览：39次中文

阅读说明：本技术 一种1,3,4-恶二唑类神经氨酸酶抑制剂及其制备方法与应用 (1,3, 4-oxadiazole neuraminidase inhibitor and preparation method and application thereof ) 是由程利平余微庞婉于 2021-06-29 设计创作，主要内容包括：本发明涉及一种1,3,4-恶二唑类神经氨酸酶抑制剂及其制备方法与应用,该抑制剂具有式(I)所示的结构：制备方法具体为：(1)将苯胺、氯乙酰氯、三乙胺反应后经后处理得到式(II)中间体；(2)将苯甲酰肼,二硫化碳和氢氧化钾反应后经后处理得到式(III)中间体；(3)取式(II)中间体和式(III)中间体溶于有机溶剂中,反应后经后处理得到式(I)所示的抑制剂。与现有技术相比,本发明的化合物结构新颖,实验表明具有良好的神经氨酸酶抑制活性,可用于制备抑制神经氨酸酶活性的药物。(The invention relates to a 1,3, 4-oxadiazole neuraminidase inhibitor and a preparation method and application thereof, wherein the inhibitor has a structure shown in a formula (I):)

1. A 1,3, 4-oxadiazole neuraminidase inhibitor having the structure of formula (I):

R₁selected from any one of the following structural formulas:

wherein X is C, F, Cl, Br or I,

R₂selected from any one of the following structural formulas:

wherein X ═ C, F, Cl, Br, or I;

2. the 1,3, 4-oxadiazole neuraminidase inhibitor according to claim 1,

R₁is selected fromX is C, F or Cl,Any one of the above;

R₂is selected fromAny one of them.

3. The inhibitor of 1,3, 4-oxadiazole neuraminidase according to claim 2, which has one of the following chemical structures:

4. the inhibitor of 1,3, 4-oxadiazole neuraminidase according to claim 3, having the formula:

5. the process for preparing a 1,3, 4-oxadiazole neuraminidase inhibitor according to claim 1, which comprises the following steps:

the method specifically comprises the following steps:

(1) reacting aniline, chloracetyl chloride and triethylamine, and then carrying out post-treatment to obtain an intermediate of a formula (II);

(2) reacting benzoyl hydrazine, carbon disulfide and potassium hydroxide, and then carrying out post-treatment to obtain an intermediate of a formula (III);

(3) dissolving the intermediate shown in the formula (II) and the intermediate shown in the formula (III) in an organic solvent, reacting, and carrying out post-treatment to obtain the 1,3, 4-oxadiazole inhibitor shown in the formula (I).

6. The preparation method of the 1,3, 4-oxadiazole neuraminidase inhibitor according to claim 5, wherein in the step (1), the reaction temperature is 0-20 ℃, the reaction time is 8-24h, and the post-treatment process comprises: after the reaction is finished, 1moL of the compound is used^-1The hydrochloric acid solution, saturated sodium bicarbonate solution and saturated brine were washed, the organic phase was dried over anhydrous sodium sulfate, and the solvent was removed in vacuo to give an intermediate of formula (II).

7. The preparation method of the 1,3, 4-oxadiazole neuraminidase inhibitor according to claim 5, wherein in the step (2), the reaction temperature is 25-80 ℃, the reaction time is 14-48h, and the post-treatment process comprises: and (3) taking out the reaction system, cooling, pouring the reaction solution into ice water, adjusting the pH value to 3 by using dilute hydrochloric acid, carrying out filtration operation when the solid is completely separated out, washing the filter cake by using the ice water, drying the filter cake at normal temperature, and finally recrystallizing by using ethanol to obtain the intermediate of the formula (III).

8. The preparation method of the 1,3, 4-oxadiazole neuraminidase inhibitor according to claim 5, wherein in the step (3), the reaction temperature is 15-25 ℃, the reaction time is 6-12h, and the post-treatment process comprises: taking out the reaction system, cooling, carrying out suction filtration at normal pressure to obtain mother liquor, carrying out rotary evaporation, sample mixing and column chromatography to obtain the inhibitor shown in the formula (I).

9. The process for producing a 1,3, 4-oxadiazole neuraminidase inhibitor according to claim 5,

in the step (1), triethylamine is used as a catalyst, an organic solvent is dry dichloromethane, and the adding amount ratio of the aniline, the chloracetyl chloride, the triethylamine and the organic solvent is (3-8) mmol, (3-8) mmol: (10-40) ml;

in the step (2), potassium hydroxide is used as a catalyst, an organic solvent is dry ethanol, and the addition ratio of the benzoyl hydrazine, the carbon disulfide and the potassium hydroxide is 5mmol (5-10) mmol: (5-10) mmol;

in the step (3), acetone, acetonitrile or DMF is adopted as an organic solvent, and the adding amount ratio of the intermediate in the formula (II), the intermediate in the formula (III), anhydrous potassium carbonate, potassium iodide to the organic solvent is (1-1.5) mmol: (0.1-1) mmol: (10-20) ml.

10. Use of a 1,3, 4-oxadiazole neuraminidase inhibitor according to any one of claims 1 to 4 in the preparation of a medicament capable of inhibiting neuraminidase activity.

Technical Field

The invention belongs to the technical field of biological medicines, and particularly relates to a 1,3, 4-oxadiazole neuraminidase inhibitor as well as a preparation method and application thereof.

Background

Neuraminidase is a glycoprotein distributed on an influenza virus envelope, and can assist mature influenza viruses to separate from original host cells to infect new cells, so that neuraminidase is one of important targets for development of anti-influenza virus medicines.

Currently, the FDA approved drugs in the united states against influenza virus are only 6, 2M 2 proton channel inhibitors (amantadine and rimantadine), 3 neuraminidase inhibitors (zanamivir, oseltamivir, and peramivir), and 1 RNA-dependent RNA polymerase inhibitor (soffit). Anti-influenza drugs developed with neuraminidase as a target can be classified into the following classes according to structure: cyclohexenes, pyrans, pyrrolidines, benzoic acid derivatives, natural products, and the like. The most widely used anti-influenza drug is tamiflu at present, but with the wide use of the drug, the drug resistance of influenza virus to tamiflu also appears, and the production raw materials of tamiflu are extremely expensive and the synthesis process is complex.

Therefore, it is urgent to develop a novel neuraminidase inhibitor having a better inhibitory effect.

Disclosure of Invention

The invention aims to solve the problems and provide a 1,3, 4-oxadiazole neuraminidase inhibitor and a preparation method and application thereof.

The purpose of the invention is realized by the following technical scheme:

a1, 3, 4-oxadiazole neuraminidase inhibitor having the structure of formula (I):

wherein, R is₁Selected from any one of the following structural formulas:

(X ═ C, F, Cl, Br or I),

R₂Selected from any one of the following structural formulas:

(X ═ C, F, Cl, Br or I),

Preferably, R₁Is selected from(X-C, F or Cl),Any one of them.

R₂Is selected fromAny one of them.

Further preferably, the inhibitor has the following structure:

most preferably, the inhibitor has the structure:

the preparation method of the 1,3, 4-oxadiazole neuraminidase inhibitor is shown as the following equation:

the preparation method specifically comprises the following steps:

(1) reacting aniline, chloracetyl chloride and triethylamine, and then carrying out post-treatment to obtain an intermediate of a formula (II);

(2) reacting benzoyl hydrazine, carbon disulfide and potassium hydroxide, and then carrying out post-treatment to obtain an intermediate of a formula (III);

In the step (1), triethylamine is used as a catalyst, and the organic solvent is dried dichloromethane.

In the step (1), the reaction system is placed at the temperature of 0-20 ℃, preferably 15 ℃, and the reaction time is 8-24h, preferably 24 h.

In the step (1), the post-treatment process specifically comprises the following steps: after the reaction is finished, the reaction solution is added,sequentially using 1moL of^-1The hydrochloric acid solution, saturated sodium bicarbonate solution and saturated brine are washed, the organic phase is dried over anhydrous sodium sulfate and the solvent is removed in vacuo to give the intermediate of formula (II).

In the step (1), the adding amount ratio of the aniline, the chloracetyl chloride, the triethylamine and the organic solvent is (3-8) mmol, (3-8) mmol: (10-40) ml, preferably 5mmol:5mmol:5mmol:30 ml.

In the step (2), potassium hydroxide is used as a catalyst, and the organic solvent is dried ethanol.

In the step (2), the reaction system is placed at the temperature of 25-100 ℃, preferably 80 ℃, and the reaction time is 14-48h, preferably 24 h.

And (2) taking out the reaction system, cooling, pouring the reaction liquid into ice water, adjusting the pH value to 3 by using dilute hydrochloric acid, carrying out filtering operation when the solid is completely separated out, washing a filter cake by using the ice water, drying the filter cake at normal temperature, and finally recrystallizing by using ethanol to obtain the intermediate of the formula (III).

In the step (2), the adding amount ratio of the benzoyl hydrazine, the carbon disulfide and the potassium hydroxide is 5mmol (5-10) mmol: (5-10) mmol, preferably 5mmol:10 mmol:5 mmol.

In the step (3), the organic solvent is acetone, acetonitrile or DMF, preferably acetone.

In the step (3), the reaction system is placed in an oil bath for heating, the reaction temperature is 15-25 ℃, the reaction time is preferably 20 ℃, and the reaction time is 8-24h, and the reaction time is preferably 24 h.

In the step (3), the post-treatment process specifically comprises the following steps: taking out the reaction system, cooling, carrying out suction filtration at normal pressure to obtain mother liquor, carrying out rotary evaporation, mixing samples, and carrying out column chromatography to obtain the inhibitor shown in the formula (I).

In the step (3), the adding amount ratio of the intermediate of the formula (II), the intermediate of the formula (III), anhydrous potassium carbonate, potassium iodide and the organic solvent is (1-1.5) mmol, (1-1.5) mmol: (0.1-1) mmol: (10-20) ml, preferably 1.2mmol:1mmol: 0.1 mmol: 15 ml.

The 1,3, 4-oxadiazole neuraminidase inhibitor can be used for preparing a medicament capable of inhibiting the activity of neuraminidase.

The invention utilizes a receptor-based molecular docking virtual screening method to screen 116708 compounds from a ZINC database to obtain one compound theoretically having neuraminidase inhibition activity, then modifies the structure of the compound, designs more reasonable compounds, performs neuraminidase test on ten compounds, takes oseltamivir acid (OSC) as a positive control, wherein IC of the OSC is IC₅₀The value was 0.082. mu.M. IC of the following two compounds synthesized by the present invention₅₀The values (0.027. mu.M and 0.032. mu.M) are both less than the IC for the positive control OSC₅₀The value of 0.082 μ M shows that it has better neuraminidase inhibitory activity than oseltamivir acid:

among them, the compounds having the best inhibitory effectIC thereof₅₀The value was 0.027. mu.M, and it had very excellent neuraminidase inhibitory activity.

The invention provides a neuraminidase inhibitor with a new skeleton structure and a preparation method and application thereof, the synthesis method is simple, the prepared inhibitor has good neuraminidase inhibition activity and excellent neuraminidase inhibition effect, and is expected to be applied to preparation of drugs for inhibiting the neuraminidase activity.

Detailed Description

The present invention is described in detail below with reference to specific examples, but the present invention is not limited thereto in any way.

A1, 3, 4-oxadiazole neuraminidase inhibitor having the structure of formula (I):

wherein, R is₁Is selected from any of the following structural formulasOne of them is:

(X ═ C, F, Cl, Br or I),

R₂Selected from any one of the following structural formulas:

(X ═ C, F, Cl, Br or I),

A process for preparing the 1,3, 4-oxadiazole neuraminidase inhibitor as described above, the equation of which is shown below:

the preparation method specifically comprises the following steps:

(1) reacting aniline, chloracetyl chloride and triethylamine, and then carrying out post-treatment to obtain an intermediate of a formula (II);

(2) reacting benzoyl hydrazine, carbon disulfide and potassium hydroxide, and then carrying out post-treatment to obtain an intermediate of a formula (III);

in the step (1), triethylamine is used as a catalyst, the organic solvent is dichloromethane, the reaction system is placed at the temperature of 0-20 ℃, preferably 15 ℃, the reaction time is 8-24h, preferably 24h, and the post-treatment process specifically comprises the following steps: after the reaction is finished, 1moL of the compound is used^-1The hydrochloric acid solution, saturated sodium bicarbonate solution and saturated common salt solution are washed, the organic phase is dried by anhydrous sodium sulfate, the solvent is removed in vacuum, and the intermediate of the formula (II) is obtained, wherein the adding amount ratio of the aniline, the chloracetyl chloride, the triethylamine and the organic solvent is (3-8) mmol, (10-40) ml, preferably 5mmol:5mmol:5mmol:30 ml.

In the step (2), the reaction system is placed at the temperature of 25-100 ℃, preferably 80 ℃, and the reaction time is 14-48h, preferably 24 h. The post-treatment process specifically comprises the following steps: and (3) taking out the reaction system, cooling, pouring the reaction solution into ice water, adjusting the pH value to 3 by using dilute hydrochloric acid, carrying out filtration operation when the solid is completely separated out, washing the filter cake by using the ice water, drying the filter cake at normal temperature, and finally recrystallizing by using ethanol to obtain the intermediate of the formula (III). The addition ratio of the benzoyl hydrazine to the carbon disulfide to the potassium hydroxide is 5mmol (5-10) mmol: (5-10) mmol, preferably 5mmol:10 mmol:5 mmol.

In the step (3), acetone, acetonitrile and DMF are adopted as the organic solvent, and acetone is preferred. The reaction system is placed in an oil bath for heating, the reaction temperature is 15-25 ℃, the reaction temperature is preferably 20 ℃, and the reaction time is 8-24h, preferably 24 h. The post-treatment process specifically comprises the following steps: taking out the reaction system, cooling, carrying out suction filtration at normal pressure to obtain mother liquor, carrying out rotary evaporation, mixing samples, and carrying out column chromatography to obtain the inhibitor shown in the formula (I). The addition amount ratio of the intermediate of the formula (II), the intermediate of the formula (III), anhydrous potassium carbonate, potassium iodide and an organic solvent is (1-1.5) mmol, (1-1.5) mmol: (0.1-1) mmol: (10-20) ml, preferably 1.2mmol:1mmol: 0.1 mmol: 15 ml.

The 1,3, 4-oxadiazole neuraminidase inhibitor is applied to preparation of a medicine capable of inhibiting neuraminidase activity.

The following are specific examples:

example 1

A preparation method of a 1,3, 4-oxadiazole neuraminidase inhibitor has a structural formula shown in a formula I:

the specific synthesis steps are as follows:

(1) 0.7g (5mmol) of 3-fluorophenylethylamine and 0.51g (5mmol) of triethylamine were accurately weighed into a 250mL round-bottomed flask, 30mL of dichloromethane were poured into the flask, the flask was stirred in an ice bath under nitrogen protection, and 0.37mL (5mmol) of chloroacetyl chloride was added dropwise into the flask with a 1mL disposable syringe. After the dropwise addition, the mixture is stirred and reacted for 24 hours at 15 ℃, and after the reaction is finished, 1moL of the mixture is sequentially used^-1The hydrochloric acid solution, saturated sodium bicarbonate solution and saturated brine are washed, the organic phase is dried over anhydrous sodium sulfate and the solvent is removed in vacuo to give the intermediate of formula (II).

(2) Accurately weighing 0.76g (5mmol) of 4-hydroxybenzoyl hydrazine and 0.28g (5mmol) of potassium hydroxide in a 250ml round-bottom flask, adding 50ml of ethanol and 10ml of water, stirring and dissolving at normal temperature, after the solid is completely dissolved, taking 0.76g (10mmol) of carbon disulfide, diluting with 50ml of ethanol, slowly dropwise adding into the system by using a constant-pressure dropping funnel, and reacting for 8 hours at 85 ℃. And after the reaction is finished, taking out the reaction system, cooling, pouring the reaction liquid into ice water, adjusting the pH value to 3 by using dilute hydrochloric acid, filtering when the solid is completely separated out, washing a filter cake by using the ice water, drying the filter cake at normal temperature, and recrystallizing by using ethanol to obtain the intermediate of the formula (III).

(3) Accurately weighing 0.22g (1.2mmol) of the intermediate (II), 0.19g (1mmol) of the intermediate (III), 0.138g (1mmol) of potassium carbonate and 0.017g (0.1mmol) of potassium iodide in a 50ml round bottom flask, adding 20ml of acetone, placing in a constant temperature oil bath kettle, heating and stirring at 20 ℃ for reaction for 12 hours, taking out and cooling the reaction liquid, taking out the reaction system for cooling, carrying out suction filtration at normal pressure to obtain a mother liquor, carrying out rotary evaporation, mixing a sample and carrying out column chromatography to obtain the inhibitor shown in the formula (I).

The prepared inhibitor is tested for inhibiting the activity of neuraminidase:

1. laboratory instruments and materials

A multifunctional fluorescent microplate reader, model SP-Max 3500FL, Shanghai flash spectrum Biotech limited;

an ultra-clean bench;

bond A3Pipette manual single-channel adjustable pipettor, 0.5-10ul, 10-100ul, 100 and 1000ul of tylosin science and technology;

96-well plate (black), sterilized, kangning;

H5N1 neuraminidase available from Beijing Yi Qiao Shen science and technology, Inc.; the fluorogenic substrate 2' - (4-methylumbelliferone) - α -D-acetylneuraminic acid sodium hydrate (4-MUNANA) (Sigma, M8639) used in the enzyme inhibition experiments was purchased from Sigma; 2- (N-morpholine) ethanesulfonic acid (MES), calcium chloride, sodium hydroxide, absolute ethanol, purchased from Tatan technology.

A positive control drug, Oseltamivir acid (abbreviated as OSC), shanghai haokang biotechnology limited.

2. Experimental methods

Dissolving a positive control drug and a target compound (namely the prepared 2- (N- (3, 4-dichlorophenyl) carbonyl methylene sulfydryl) -5- (4-chlorphenyl) -1,3, 4-oxadiazole) in DMSO, preparing the initial concentration into 1000 mu m/L, diluting the initial concentration into 6 concentration gradients according to a multiple ratio, and preparing three groups of concentration gradients sequentially, wherein each concentration gradient is 200 mu m/L, 40 mu m/L, 8 mu m/L, 1.6 mu m/L, 0.32 mu m/L and 0.064 mu m/L;

2.1 sample preparation for detection

a. Buffer (33mM MES, 4mM CaCl)₂) Adding 70 mul of the enzyme-linked immunosorbent assay (ELISA) plate into each hole;

b. adding 10 mul of neuraminidase into each hole;

c. adding 10 mul of the prepared neuraminidase inhibitor sample to be detected or the positive control drug sample with the concentration into each hole, and simultaneously setting three groups of blank test controls;

d. neuraminidase substrate (100. mu.M.L)^-14-MUNANA) 10. mu.l per well.

2.2 detection

a. Placing the 96-well plate in a multifunctional fluorescent microplate reader, and shaking and uniformly mixing for 1 minute;

b. setting the temperature to be 37 ℃, and incubating for 5 minutes to ensure that the neuraminidase and the sample to be detected are fully mixed and interacted;

c. taking out the 96-well plate, and adding 10 mu l of neuraminidase fluorescent substrate into each well;

d. placing the mixture in a multifunctional fluorescent microplate reader again, and shaking and uniformly mixing for 1 minute;

e. after incubation at 37 ℃ for 30 minutes, the cells were removed and 150. mu.l of stop solution (14 mM. multidot.L) was added to each well^-183% ethanol water solution of NaOH), placing the mixture in a multifunctional fluorescent microplate reader again, shaking and uniformly mixing for 1 minute, setting the excitation wavelength to be 355nm and the emission wavelength to be 460nm, and starting fluorescence intensity (RFU) measurement after the incubation is finished;

f. the above procedure was repeated to perform 3 parallel experiments.

Note: the first well in the 96-well plate was used as a blank, no sample to be tested was added, and 10 μ l of DMSO solution was added.

Calculating the average value of the inhibition rate of the sample under each gradient concentration in each parallel experiment, and then fitting the corresponding IC through Origin₅₀The value is obtained.

2.3 results of the experiment

The positive control drug and the target compound are prepared into mixed solutions with initial concentrations of 1000 mu m/L by DMSO solutions, the two mixed solutions are diluted into 6 concentration gradients according to a multiple ratio, the concentration gradients are 200 mu m/L, 40 mu m/L, 8 mu m/L, 1.6 mu m/L, 0.32 mu m/L and 0.064 mu m/L in sequence, and three groups are prepared in sequence for each concentration gradient. 70 mul of neuraminidase buffer solution, 10 mul of neuraminidase and positive control drug samples of each gradient concentration to be detected are added into a 96-hole black fluorescent enzyme label plate, and three groups of blank test controls are arranged at the same time. Shaking in a multifunctional fluorescent microplate reader for 1 min, mixing, and incubating at 37 deg.C for 5 min; taking out 96-well enzyme-linked immunosorbent assay plate, adding 10 μ L neuraminidase substrate into each well, shaking for 1 min, mixing, incubating at 37 deg.C for 30min, taking out, adding 150 μ L stop buffer (14 mM. L) into each well^-1And (3) putting the NaOH aqueous solution in 83% ethanol solution) into the multifunctional luciferase reader again, uniformly mixing the NaOH aqueous solution and the NaOH aqueous solution by shaking for 1 minute, setting the excitation wavelength to be 355nm and the emission wavelength to be 460nm, and starting to measure the fluorescence intensity (RFU) after the incubation is finished. Three experiments were performed in parallel. Calculating outThe average value of the inhibition rate of the sample under each gradient concentration in each parallel experiment is obtained, and then the corresponding IC is obtained by Origin fitting₅₀The inhibition rate of each sample is calculated, and the corresponding IC is fitted by Origin₅₀Value, IC thereof₅₀IC of 0.027. mu.M, positive control₅₀The value was 0.082. mu.M.

The product was obtained as 2- (N- (3-fluorophenethyl) carbonylmethylenemercapto) -5- (4-hydroxyphenyl) -1,3, 4-oxadiazole as a white solid in 56% yield.

¹H NMR(500MHz,DMSO-d₆)δ10.35(s,1H),8.41(t,J＝5.8Hz,1H),7.79(d,J＝8.2Hz,2H),7.29(q,J＝7.5Hz,1H),7.00(m,5H),4.04(s,2H),3.35(q,J＝6.9Hz,2H),2.74(t,J＝7.1Hz,2H).¹³C NMR(125MHz,DMSO-d₆)δ166.55,165.78,163.61,162.61,161.67,161.26,142.64,130.51,128.82,125.25,116.62,115.71,114.24,113.27,40.76,36.14,34.98.

Example 2